APLN and metabolic syndrome: While alterations in vascular biomarkers such as NO, apelin, noradrenaline, and prostacyclin have also been documented in metabolic conditions like obesity, metabolic syndrome, and type 2 diabetes mellitus, the pattern and extent of dysregulation observed in our PCOS cohort may represent a distinct pathophysiological signature.